Drug Resistance in Osteosarcoma
Author Information
Author(s): SD Shnyder, AJ Hayes, J Pringle, CW Archer
Primary Institution: Anatomy Unit, School of Molecular & Medical Biosciences, Cardiff, UK; Institute of Orthopaedics, University College London, England
Hypothesis
Does the expression of P-glycoprotein and metallothionein correlate with patient survival in osteosarcoma?
Conclusion
Lack of expression of P-glycoprotein and metallothionein does not appear to confer any advantage in terms of patient survival in osteosarcoma.
Supporting Evidence
- The study assessed the expression of P-glycoprotein and metallothionein in biopsy material from 18 patients.
- Statistical analysis showed no significant differences in survival rates between expressors and non-expressors of P-glycoprotein and metallothionein.
- Previous studies have shown conflicting results regarding the correlation between P-glycoprotein expression and therapy response.
Takeaway
This study looked at whether certain proteins in cancer cells affect how well patients with osteosarcoma respond to treatment, and found that they don't seem to make a difference.
Methodology
Immunohistochemical assessment of P-glycoprotein and metallothionein expression in biopsy samples from patients with osteosarcoma, followed by statistical analysis of survival data.
Limitations
The study only included patients with known 5-year follow-up data, which may limit the generalizability of the findings.
Participant Demographics
Patients with clinically diagnosed high-grade malignant osteosarcoma.
Statistical Information
P-Value
0.81 for C219; 0.88 for E9
Statistical Significance
p=0.81 for C219; p=0.88 for E9
Want to read the original?
Access the complete publication on the publisher's website